Incretin Atlas › Trials › UBT251 phase 2 (obesity)
UBT251 phase 2 (obesity)
UBT251 · obesity
Design
- Molecule(s)
- UBT251
- Population
- obesity
- Phase
- 2
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UBT251 4.0 mg (start 1.0 mg) | obesity china | 24 | — | — | —−19.7 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | verified |
| UBT251 6.0 mg | obesity china | 24 | — | — | —−18.7 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | verified |
| UBT251 2.0 mg | obesity china | 24 | — | — | —−13.6 % vs −2.0 % estimand not specified | — | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- UBT251 4.0 mg (start 1.0 mg): Estimand not stated in the abstract (ANCOVA LS means); both models agree Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
- UBT251 6.0 mg: Estimand not stated in the abstract (ANCOVA LS means); both models agree Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
- UBT251 2.0 mg: Estimand not stated in the abstract (ANCOVA LS means); both models agree Peer-reviewed paper (Cell Metab 2026) confirms the range of −13.6 % to −19.7 % vs −2.0 % with placebo at 24 weeks; per-dose values come from the EASD 2026 abstract until the full text is available.
Verbatim quotes from the source (3)
- UBT251 4.0 mg (start 1.0 mg) · weight_unsp · Results
LSM percentage change in weight
- UBT251 6.0 mg · weight_unsp · Results
LSM percentage change in weight
- UBT251 2.0 mg · weight_unsp · Results
LSM percentage change in weight
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd63850.
- Zhou Z, Cheng Z, Jin P, Yang G, Wang H, Shi B, et al. UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial. Cell Metab. 2026. PMID: 42843337.
How to cite this page
Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.